Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test

FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasseur, Damien, Sassi, Hela, Bayle, Arnaud, Tagliamento, Marco, Besse, Benjamin, Marzac, Christophe, Arbab, Ahmadreza, Auger, Nathalie, Cotteret, Sophie, Aldea, Mihaela, Blanc-Durand, Félix, Géraud, Arthur, Gazzah, Anas, Loriot, Yohann, Hollebecque, Antoine, Martín-Romano, Patricia, Ngo-Camus, Maud, Nicotra, Claudio, Ponce, Santiago, Sakkal, Madona, Caron, Olivier, Smolenschi, Cristina, Micol, Jean-Baptiste, Italiano, Antoine, Rouleau, Etienne, Lacroix, Ludovic
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221453/
https://www.ncbi.nlm.nih.gov/pubmed/35741030
http://dx.doi.org/10.3390/cells11121901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221453/
https://www.ncbi.nlm.nih.gov/pubmed/35741030
http://dx.doi.org/10.3390/cells11121901

Ejemplares similares